24 papers · ranked by Valyu relevance
Rahul Khetan, Robin Curtis, Charlotte M. Deane, Johannes Thorling Hadsund + 8 more
'Johannes Thorling Hadsund' 'Uddipan Kar' 'Konrad Krawczyk' 'Daisuke Kuroda' 'Sarah A. Robinson' 'Pietro Sormanni' 'Kouhei Tsumoto' 'Jim Warwicker' 'Andrew C.R. Martin'] Title: ABSTRACT Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical…
Varun Dewaker, Vivek Kumar Morya, Yoo Hee Kim, Sung Taek Park + 2 more
'Hyeong Su Kim' 'Young Ho Koh'] Antibodies play a crucial role in defending the human body against diseases, including life-threatening conditions like cancer. They mediate immune responses against foreign antigens and, in some cases, self-antigens. Over time, antibody-based technologies have evolved from monoclonal…
Ammar Arsiwala, Rebecca Bhatt, Lood van Niekerk, Porfirio Quintero-Cadena + 24 more
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g., thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and…
Ammar Arsiwala, Rebecca Bhatt, Yaoyu Yang, Porfi Quintero Cadena + 22 more
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess additional properties—collectively referred to as developability properties—that ensure favorable production, formulation, and in vivo performance. Both types of properties—comprising a…
Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M. Ismail + 3 more
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of…
Habib Bashour, Eva Smorodina, Matteo Pariset, Jahn Zhong + 11 more
Designing effective monoclonal antibody (mAb) therapeutics face a significant challenge known as “developability”, which reflects an antibody’s ability to progress through development stages based on its physicochemical properties. While natural antibody repertoires may provide valuable guidance for antibody selection…
Bian Li, Shukun Luo, Wenhua Wang, Jiahui Xu + 6 more
Selection of lead therapeutic molecules is often driven predominantly by pharmacological efficacy and safety. Candidate developability, such as biophysical properties that affect the formulation of the molecule into a product, is usually evaluated only toward the end of the drug development pipeline. The ability to…
Monica L. Fernández-Quintero, Anne Ljungars, Franz Waibl, Victor Greiff + 12 more
'Victor Greiff' 'Jan Terje Andersen' 'Torleif T. Gjølberg' 'Timothy P. Jenkins' 'Bjørn Gunnar Voldborg' 'Lise Marie Grav' 'Sandeep Kumar' 'Guy Georges' 'Hubert Kettenberger' 'Klaus R. Liedl' 'Peter M. Tessier' 'John McCafferty' 'Andreas H. Laustsen'] Title: ABSTRACT Beyond potency, a good developability profile is a…
Manar Ammar, Mikhail Samsonov, Evgeniya Gurylina, Daniel Bayzigitov
Monoclonal antibody-based therapeutics have become essential tools for treating infectious, autoimmune, and malignant diseases due to their high specificity and efficacy. As their clinical and scientific relevance continues to expand, the need for faster, more accurate and cost-effective development strategies has…
Zhao, Siqi, Moller, Joshua + 4 more
Therapeutic antibodies require not only highaffinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called 'developability'. To enable a computational framework for optimizing antibody sequences for favorable…
Gemma L. Gordon, João Gervasio, Colby Souders, Charlotte M. Deane
Developability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel bio-therapeutics such as nanobodies is more limited. Differences in structural features between antibodies and nanobodies render…
Ruei-Min Lu, Hsiao-Ling Chiang, Joyce Pei‑Yi Yuan, Hsiu-Hua Wang + 11 more
Monoclonal antibodies (mAbs) represent a major class of therapeutics with widespread clinical applications in oncology, immunology, hematology, neurology and infectious disease. Since the introduction of hybridoma technology in 1975, the field has been advanced by a succession of innovations including chimeric and…
Asif Khan, Alexander I. Cowen-Rivers, Derrick-Goh-Xin Deik, Antoine Grosnit + 10 more
'Antoine Grosnit' 'Philippe A. Robert' 'Victor Greiff' 'Eva Smorodina' 'Puneet Rawat' 'Rahmad Akbar' 'Kamil Dreczkowski' 'Rasul Tatunov' 'Dany Bou-Ammar' 'Jun Wang' 'Haitham Bou Ammar'] Antibodies are canonically Y-shaped multimeric proteins capable of highly specific molecular recognition. The CDRH3 region located at…
Andreas Evers, Shipra Malhotra, Vanita D. Sood
The recognition of the importance of drug-like properties beyond potency to reduce clinical attrition of biologics has driven significant progress in the development of in vitro and in silico tools for developability assessment of antibody sequences. It is now routine to identify and eliminate or optimize antibody hits…
Weronika Bielska, Igor Jaszczyszyn, Pawel Dudzic, Bartosz Janusz + 6 more
'Dawid Chomicz' 'Sonia Wrobel' 'Victor Greiff' 'Ryan Feehan' 'Jared Adolf-Bryfogle' 'Konrad Krawczyk'] Abstract: Machine learning applications in protein sciences have ushered in a new era for designing molecules in silico. Antibodies, which currently form the largest group of biologics in clinical use, stand to…
Latent Labs Team, Henry Kenlay, Daniella Pretorius, Jonathan Crabbé + 14 more
Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and nonimmunogenic from the start. Here we introduce Latent-X2, a frontier generative model that achieves this goal through zero-shot design of antibodies with strong binding affinities, drug-like…
Authors not listed
Genetically encoded covalent warheads at the protein-protein interface, enable the locking of interaction from the transient complex into a stable covalent adduct, which could improve the binding affinity, selectivity, and kinetics between a protein binder and its target. Given the diverse chemical microenvironments…
Irene Shajan, Lea Rochet, Shannon Tracey, Rania Benazza + 7 more
Redirecting T cells to tumor cells by bispecific antibodies is an effective approach to treat cancer and T cell-dependent bispecific antibodies (TDBAs) are an emerging class of potent immunotherapeutic agents. By simultaneously targeting antigens on tumor cells and that on T cells, T cells are activated to kill tumor…
Zhao, Xinyan, Tang, Yi-Ching + 20 more
We introduce AbBiBench (Antibody Binding Benchmarking), a benchmarking framework for antibody binding affinity maturation and design. Unlike previous strategies that evaluate antibodies in isolation, typically by comparing them to natural sequences with metrics such as amino acid recovery rate or structural RMSD…
Authors not listed
Helicobacter pylori adhesin A (HpaA) is a surface-associated protein critical for the adhesion of H. pylori to gastric epithelial cells, which is strongly associated with an increased risk of gastric cancer. Recent elucidation of the 3D structure of HpaA offers novel opportunities for targeted therapeutic strategies to…
Brad Evans, Lai Yeung, Armen Beck, Annie Li + 3 more
The growth of therapeutic monoclonal antibodies continues to accelerate due to their success as treatments for many diseases. As new therapeutics are developed, it is increasingly important to have robust bioanalytical methods to measure the pharmacokinetics of the circulating therapeutic monoclonal antibodies (mAbs)…
Ana Díaz-Fernández, Simona Ranallo, Francesco Ricci
Here we report the development of a method for the electrochemical ultrasensitive detection of antibodies that couples the programmability and versatility of DNA-based systems with the sensitivity provided by enzymatic amplification. The platform, termed Enzyme-Linked DNA Displacement (ELIDIS), is based on the use of…
Yuchen Bai, Jie Fei, Weilin Wu, Leina Dou + 6 more
The pursuit of the limit between dimensionalities is a scientific goal with high applicability. Sandwich immunoassay, usually based on two antibodies binding two epitopes, is one of the most popular mainstay tools in both academic and industrial fields. Herein, we determined and evaluated the minimum distance of two…
Amit Patel, Rahul Sharma
The human immune system is a complex network of cells, tissues, and organs that work together to protect the body from harmful pathogens. Antibodies, also known as immunoglobulins (Ig), are small proteins that play a vital role in the immune system's defense mechanism. Among the five classes of immunoglobulins…